Chemotherapy-Induced Anemia Market Report 2026

The chemotherapy-induced anemia market size has grown strongly in recent years. It will grow from $2.81 billion in 2025 to $3.03 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing use of intensive chemotherapy regimens, rising prevalence of treatment-related anemia, expansion of oncology treatment centers, improved access to blood transfusion services, availability of supportive cancer care therapies.

The chemotherapy-induced anemia market size is expected to see strong growth in the next few years. It will grow to $4.13 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for long-acting anemia treatments, rising focus on minimizing transfusion dependency, expansion of personalized oncology care, growing adoption of home-based treatment models, advancements in anemia management drugs. Major trends in the forecast period include increasing adoption of erythropoiesis-stimulating agents, growing use of personalized anemia management plans, rising preference for early intervention therapies, expansion of outpatient anemia treatment settings, enhanced focus on patient quality of life.

The high prevalence of cancer and anemia is anticipated to drive the growth of the chemotherapy-induced anemia market in the coming years. Cancer is a disease in which abnormal cells grow uncontrollably and spread to other parts of the body. Among cancer patients undergoing intensive chemotherapy, with or without radiation therapy, both cancer-related anemia and chemotherapy-induced anemia (CIA) are common complications. Treatments for chemotherapy-induced anemia work by stimulating red blood cell production in the bone marrow, helping to manage anemia in affected patients. For instance, in 2023, according to Cancer Research UK, a UK-based independent cancer research organization, the incidence of head and neck cancer in the UK is expected to increase by 3% between 2023 and 2025, while deaths from head and neck cancers are projected to rise by 12% over the same period. Therefore, the high burden of cancer and anemia is fueling the growth of the chemotherapy-induced anemia market.

Major companies operating in the chemotherapy-induced anemia market are concentrating on developing advanced therapies, such as Ojjaara (momelotinib), to expand treatment options and improve outcomes for patients experiencing anemia associated with cancer therapies. The name “Ojjaara” is derived from the word “Ojaara,” symbolizing a connection to healing and wellness. For instance, in September 2023, GSK (GlaxoSmithKline), an England-based pharmaceutical company, developed Ojjaara (momelotinib) as a treatment for myelofibrosis, particularly for patients with anemia. Ojjaara is a novel therapy for myelofibrosis patients with anemia, acting by inhibiting key signaling pathways to improve blood counts, enhance quality of life, and reduce dependence on blood transfusions, making it the first and only treatment specifically indicated for this condition.

In August 2024, Pharmacosmos Group, a Denmark-based global pharmaceutical company, acquired G1 Therapeutics, Inc. for an undisclosed amount. Through this acquisition, Pharmacosmos aims to reinforce its oncology supportive care portfolio, expand its footprint in the U.S. biopharmaceutical market, and accelerate the development and commercialization of innovative therapies addressing unmet needs in cancer care. G1 Therapeutics, Inc. is a U.S.-based biopharmaceutical company that offers products for the treatment of chemotherapy-induced anemia.

Major companies operating in the chemotherapy-induced anemia market are Pfizer Inc., Johnson & Johnson, F. Hoffmann‑La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Fresenius Kabi AG, Biocon Ltd., Vifor Pharma Group, Pharmacosmos A/S, Daiichi Sankyo Company Limited, Bayer AG, Akebia Therapeutics Inc, Otsuka Pharmaceutical Co Ltd, Zydus Lifesciences Ltd, Viatris Inc, Shield Therapeutics plc, Keros Therapeutics Inc.

North America was the largest region in the chemotherapy-induced anemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy-induced anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chemotherapy-induced anemia market by raising costs of imported biologics, blood processing equipment, iron formulations, and pharmaceutical intermediates required for anemia treatment. Hospitals and oncology centers in North America and Europe are most affected due to dependence on imported ESAs and medical supplies, while Asia-Pacific faces pricing pressure in biologics manufacturing. These tariffs are increasing treatment costs and affecting procurement planning. At the same time, they are encouraging domestic biologics production, regional plasma processing capacity, and localized pharmaceutical manufacturing investments that improve long-term supply resilience.

The chemotherapy-induced anemia market research report is one of a series of new reports that provides chemotherapy-induced anemia market statistics, including chemotherapy-induced anemia industry global market size, regional shares, competitors with a chemotherapy-induced anemia market share, detailed chemotherapy-induced anemia market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced anemia industry. This chemotherapy-induced anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chemotherapy-induced anemia refers to a reduction in red blood cell levels resulting from chemotherapy treatment, which can cause symptoms such as fatigue, weakness, and reduced physical capacity. It is managed as a side effect of cancer therapy to help improve patients’ quality of life, often through the use of erythropoiesis-stimulating agents or blood transfusions.

The main types of chemotherapy-induced anemia include mild, moderate, severe, and life-threatening anemia. Mild anemia is characterized by hemoglobin levels that fall below normal ranges. Treatment approaches, including red blood cell (RBC) transfusions, erythropoiesis-stimulating agents (ESAs), and iron supplementation, are provided across various end users such as hospitals, ambulatory surgical centers, multispecialty clinics, cancer research centers, and cancer rehabilitation centers.

The chemotherapy-induced anemia market consists of sales of androxy oral, epoetin alfa injection, epogen injection, procrit injection, and aranesp injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.